Chronic Malignancies Working Party (CMWP)
Study type:
Study number:
42205691
Type of treatment:
Allogeneic
Diseases:
Myelodysplastic (MDS) or MDS/MPN
Short title:
MDS AI
Primary objective:
● To identify risk factors for survival after allo-HCT in patients with MDS.
● To develop a prognostic model for survival after allo-HCT using machine learning methods.
● To develop a prognostic model for survival after allo-HCT using machine learning methods.
Key inclusion criteria:
● Patients’ Age: All adults 18 years and more.
● Diagnosis: MDS patients.
● No of transplant: First allo-HCT only.
Period Analysed: January 2015 to January 2022.
Stem Cell Source: BM and PB regardless of HLA compatibility.
● Diagnosis: MDS patients.
● No of transplant: First allo-HCT only.
Period Analysed: January 2015 to January 2022.
Stem Cell Source: BM and PB regardless of HLA compatibility.
Country:
All EBMT member countries
Principal investigator:
Donal P. McLornan, Carmelo Gurnari, Adrián Mosquera Orgueira, Marie Robin
EBMT Study coordinator:
Joe Tuffnell
Study coordinator email:
cmwp@ebmt.org
EBMT Study Unit:
Leiden Study Unit
Reason for processing personal data:
Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.
Categories of personal data collected:
DOB/YOB, gender
Medical data already reported to the EBMT Registry
Recipients who may access the data:
Leiden Study Unit
Statistical Unit
Investigators
External statistician specialized in AI
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
Yes
Privacy notices
Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Data Protection Impact Assessments
Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results